昭衍新药(06127.HK) 发盈警，预计2024年度归属股东净利润介乎5,869万至8,803万人民币，较上年度下降77.8%-85.2%；现营业收入19.17亿至21.19亿人民币，下降10.8%-19.3%。年内，受行业竞争加剧影响，签单压力增大，订单价格下降，利润空间被压缩，导致毛利率降低，实验室服务业务净利润相应下降。加上生物资产市场价格下降，致使生物资产公允价值变动对业绩产生消极影响。(de/d)(港股报价延迟最少十五分钟。)
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2024/10/30 | 第三季业绩 | 无派息 |
| 2024/08/30 | 中期业绩 | 无派息 |
| 2024/04/29 | 第一季业绩 | 无派息 |
| 2024/03/28 | 末期业绩 | 股息：人民币 0.1600 (约相等于 0.18 港元) |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.